Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Metastatic Gastrointestinal Carcinoid Tumor: early-phase trial registry
1 of 5 indexed Metastatic Gastrointestinal Carcinoid Tumor trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #3,391 of 28,707 conditions by registered trial count.
5 US clinical trials · 1 currently recruiting · #3,391 of 28,707 conditions by registered trial count
Metastatic Gastrointestinal Carcinoid Tumor: 5 US clinical trials tracked, 1 recruiting.
Metastatic Gastrointestinal Carcinoid Tumor is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 3 of these trials.
Enrollment posture brief
Registry condition metastatic-gastrointestinal-carcinoid-tumor
OPEN 1 | RECR 20% | LATE 0 | EARLY 5 | RANK #3391 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive (20% recruiting · 10 trials)
Metastatic Gastrointestinal Carcinoid Tumor lists 1 open slots (20% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Metastatic Gastrointestinal Carcinoid Tumor on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Metastatic Gastrointestinal Carcinoid Tumor is recruiting below its size-band peers.
1 of 5 indexed trials (20%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Metastatic Gastrointestinal Carcinoid Tumor research.
National Cancer Institute (NCI) accounts for 3 of 5 trials (60%). 3 distinct sponsors appear on at least one study for this condition label.
-
Most Metastatic Gastrointestinal Carcinoid Tumor trials plan to enrol fewer than 100 people.
Median target enrolment is 93 among the 5 trials that report a genuine target (sentinel values excluded). 4 of those (80%) plan for fewer than 100 participants.
-
Metastatic Gastrointestinal Carcinoid Tumor research is mostly interventional.
5 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
5 total, page 1 of 1
EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers
Shanghai EpimAb Biotherapeutics Co.
NCT05176665
Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors
Mayo Clinic
NCT00655655
Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
National Cancer Institute (NCI)
NCT00131911
Bevacizumab and PEG-Interferon Alfa-2b in Treating Patients With Metastatic or Unresectable Carcinoid Tumors
National Cancer Institute (NCI)
NCT00055809
Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
National Cancer Institute (NCI)
NCT00397384
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Metastatic Gastrointestinal Carcinoid Tumor records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Metastatic Gastrointestinal Carcinoid Tumor trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Metastatic Gastrointestinal Carcinoid Tumor page
5 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Metastatic Gastrointestinal Carcinoid Tumor trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Metastatic Gastrointestinal Carcinoid Tumor trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Metastatic Gastrointestinal Carcinoid Tumor condition card totals 5 registered trials; most-linked intervention laboratory biomarker analysis; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.